株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全ゲノムおよびエクソームシーケンシング(WGES)市場:研究、臨床、腫瘍、病原体、アグリバイオ、消費者別 - エグゼクティブガイドおよびコンサルタントガイド付き (Sars-cov-2の全ゲノムシーケンスを含む)2020年~2024年

Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024

発行 Howe Sound Research 商品コード 943429
出版日 ページ情報 英文 528 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.65円で換算しております。
全ゲノムおよびエクソームシーケンシング(WGES)市場:研究、臨床、腫瘍、病原体、アグリバイオ、消費者別 - エグゼクティブガイドおよびコンサルタントガイド付き (Sars-cov-2の全ゲノムシーケンスを含む)2020年~2024年 Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024
出版日: 2020年06月20日 ページ情報: 英文 528 Pages
概要

当レポートは世界の全ゲノムおよびエクソームシーケンシング(WGES)市場について調査しており、市場規模、成長および抑制要因、最近の開発・進展、用途・有機体・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

i:戦略的状況分析とCOVID-19の影響

ii:エグゼクティブ、マーケティング、セールス、ビジネス開発スタッフ向けガイド

iii:経営コンサルタントおよび投資顧問のためのガイド

第1章 イントロダクションおよび市場の定義

  • 定義
    • 全ゲノムおよびエクソームシーケンシング(WGES)
    • 調査と臨床
    • 臨床腫瘍
    • 臨床病原体
    • 農業/その他
    • D2C
  • ゲノミクス革命
  • 市場の定義
    • 収益市場規模
  • 米国の医療市場と臨床検査:展望
    • 臨床検査のための米国のメディケア支出
  • ゲノムサイズ
    • コスト、価格、ゲノムサイズ、価格設定

第2章 市場概要

  • 市場参入企業
    • 機器メーカー
    • 独立ラボ:特殊/僻地
    • 独立ラボ:国/地域
    • 独立ラボ:分析
    • 公立国立/地域ラボ
    • 病院ラボ
    • 医師ラボ
    • DTCラボ
    • シーケンシングラボ
    • 監査機関
  • 市場、例、および考察
    • 消費者向けの2つのアプローチ
    • 調査市場
    • 臨床理解生殖細胞系列と体細胞
    • 病原体検査
    • アグリバイオのビッグビジネス
  • 産業構造
    • 病院の検査シェア
    • 規模の経済
    • 機器メーカーの役割
    • ヘルスケア業界の影響

第3章 市場動向

  • 成長要因
    • 診断要因
    • その他のコードの解釈
    • 農業の変化
    • 不妊治療技術の到来
    • 病原体の課題
  • 抑制要因
    • 競争の激化による低価格化
    • 低コスト化
    • ヘルスケア費の懸念
    • ウェルネスのデメリット
    • GMO反対運動
  • 測定シーケンス
    • コストの低下による産業構造の変化
    • 現在のNGS装置仕様のリスト
    • Illumina
    • ION
    • Pacific Biosystems
    • Roche
    • SOLiD
    • Oxford Nanopore
    • ターゲットシーケンスへのCRISPRの採用
    • 新しいシーケンス技術、など

第4章 WGESの最近の進展

  • 最近の開発

第5章 主要企業のプロファイル

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • 富士フイルム和光純薬株式会社
  • 富士レビオ株式会社
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

第6章 世界の市場

  • 国別
  • 用途別
  • 有機体

第7章 市場分析:用途別

  • 調査
  • 臨床人体
  • 臨床腫瘍
  • 臨床病原体
  • D2C
  • 農業/その他

第8章 市場分析:有機体別

  • 人間
  • 病原菌
  • その他の生物

第9章 全ゲノムシーケンスの将来像

付録

  • i. 米国メディケアシステム:2020年1月の研究室料金スケジュール
  • II SARS-CoV-2の全ゲノムシーケンス
  • III 調査手法
図表

Table of Tables

  • Table 1: The Base Pairs
  • Table 2: Most Common Traditional Genetic Disorders
  • Table 3: Lab Spending 2014 to 2024
  • Table 4: List of GLOBAL SEQUENCING LOCATIONS
  • Table 5: Market Players by Type
  • Table 6: The Different Markets for Whole Genome Sequencing
  • Table 7: DTC Sub Segments
  • Table 8: Roles of WGS in AgriBio
  • Table 9: The Factors Driving Growth
  • Table 10: Factors Limiting Growth
  • Table 11: - Listing of Current NGS Instrument Specifications
  • Table 12: Six New Sequencing Technologies
  • Table 13: - Global Companion Diagnostic Market by Region
  • Table 14: Global Market by Application
  • Table 15: Global Market by Organism
  • Table 16: Research by Country
  • Table 17: Clinical Human by Country
  • Table 18: Clinical Tumor by Country
  • Table 19: Clinical Pathogen by Country
  • Table 20: Direct to Consumer by Country
  • Table 21: Agriculture/Other by Country
  • Table 22: Human by Country
  • Table 23: Pathogen by Country
  • Table 24: Other Organism by Country
  • Table 25: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Size of Genome for Various Species
  • Figure 3: - Cost To Sequence a Human Genome
  • Figure 4: Base Year Country Market Share Chart
  • Figure 5: CDx Market by Application - Base vs. Final Year
  • Figure 6: CDx Market by Application Base Year
  • Figure 7: CDx Market by Application Final Year
  • Figure 8: Application Type Share by Year
  • Figure 9: by Application Segment Growth
  • Figure 10: by Organism - Base vs. Final Year
  • Figure 11: by Organism Market Base Year
  • Figure 12: by Organism Market Final Year
  • Figure 13: by Organism Share by Year
  • Figure 14: by Organism Segment Growth
  • Figure 15: Research Growth
  • Figure 16: Clinical Human Growth
  • Figure 17: Clinical Tumor Growth
  • Figure 18: Clinical Pathogen Growth
  • Figure 19: Direct to Consumer Growth
  • Figure 20: Agriculture/Other Growth
  • Figure 21: Human Growth
  • Figure 22: Pathogen Growth
  • Figure 23: Other Organism Growth
目次

OVERVIEW:

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Whole Genome Sequencing Definition In This Report
    • 1.1.1. Whole and Exome Sequencing
    • 1.1.2. Research and Clinical
    • 1.1.3. Clinical Tumor
    • 1.1.4. Clinical Pathogen
    • 1.1.5. Agri/Other
    • 1.1.6. Direct to Consumer
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for laboratory testing
  • 1.5. Sizing the Genome-Not What You Think
    • 1.5.1. Cost, Price and Genome Size, Pricing Practice

1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE-Location & Contacts

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Instrument Manufacturer
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Sequencing Labs
    • 2.1.10. Audit body
  • 2.2. Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1. Direct to Consumer-Two Approaches
      • 2.2.1.1. The New Age of Medical Information
      • 2.2.1.2. Dangers in DTC-WGS-Health Costs and Regulation
      • 2.2.1.3. Newborn and Prenatal-A Brave New World
      • 2.2.1.4. DTC-How Many Segments?
    • 2.2.2. Research Markets
      • 2.2.2.1. Research Funding and Capital Expense
      • 2.2.2.2. WGS Datasets Preferred
      • 2.2.2.3. Existing research repurposed
      • 2.2.2.4. Organism Wide Market
      • 2.2.2.5. Service Suppliers Respond
    • 2.2.3. Clinical-Understanding Germline and Somatic
      • 2.2.3.1. Somatic-Chasing Mutations and Pharmacogenomics
    • 2.2.4. Pathogen Testing
      • 2.2.4.1. The Hepatitis C Story
      • 2.2.4.2. Will the Microbiology Department Disappear?
    • 2.2.5. AgriBio-Big Business
      • 2.2.5.1. GMO is Here to Stay
      • 2.2.5.2. WGS Benefits and Risks
      • 2.2.5.3. The New Agriculture
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Instrument Manufacturer Role
    • 2.3.4. Healthcare Industry Impacts-Still Struggling
      • 2.3.4.1. Can the Healthcare Industry Adapt?
      • 2.3.4.2. Genetic Counselling as an Industry
      • 2.3.4.3. WGES Adoption and Cannibalization
      • 2.3.4.4. The Meaning of Grail

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Diagnostic Factors
    • 3.1.2. Interpreting the Code Otherwise
    • 3.1.3. Changes in Agriculture
    • 3.1.4. Fertility Technology Comes of Age
    • 3.1.5. Pathogen Challenges
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Healthcare Cost Concerns Curtail Growth
    • 3.2.4. Wellness has a downside
    • 3.2.5. GMO Opposition Movement
  • 3.3. Sequencing Instrumentation
    • 3.3.1. Instrumentation Tenacity
    • 3.3.2. Declining Cost Changes Industry Structure
    • 3.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 3.3.4. Illumina
    • 3.3.5. ION
    • 3.3.6. Pacific Biosystems
    • 3.3.7. Roche 454
    • 3.3.8. SOLiD
    • 3.3.9. Oxford Nanopore
      • 3.3.9.1. What is Oxford Nanopore Sequencing?
      • 3.3.9.2. What can Oxford Nanopore Sequencingt be used for?
      • 3.3.9.3. Oxford Nanopore Products
    • 3.3.10. Long Reads-Further Segmentation
    • 3.3.11. Linked Reads
    • 3.3.12. Targeted Sequencing Adopts CRISPR
    • 3.3.13. New Sequencing Technologies
      • 3.3.13.1. RNAP sequencing
      • 3.3.13.2. In vitro virus high-throughput sequencing
      • 3.3.13.3. Tunnelling currents DNA sequencing
      • 3.3.13.4. Sequencing by hybridization
      • 3.3.13.5. Sequencing with mass spectrometry
      • 3.3.13.6. Microfluidic Sanger sequencing
      • 3.3.13.7. Microscopy-based techniques

4. WGES Recent Developments

  • 4.1. Recent Developments-Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Illumina Achieves First FDA EAU for NGS-Based SARS-CoV-2 Test
      • C2i Genomics to Launch Trials for MRD Detection Tech
      • Roche Acquires Sequencing Company Stratos Genomics
      • UK COVID-19 Sequencing Consortium Launches With £20M in Government, Wellcome Trust Funding
      • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
      • Experience From Centralized Genomic Medicine Lab
      • MGI to Enable $100 Human Genome
      • Nebula Genomics offers $299 WGS
      • Team to Study Campylobacter Omics
      • Veritas Genetics Restarts US Business
      • NEOGEN, Gencove partner to advance animal genomics
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • Veritas Cuts WGS Price by 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot

5. Profiles of Key Companies

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

6. The Global Market for Whole Genome Sequencing

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart - Global Market by Country
  • 6.2. Global Market by Application - Overview
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Global Market by Application-Base/Final Year Comparison
    • 6.2.3. Chart-Global Market by Application-Base Year
    • 6.2.4. Chart-Global Market by Application-Final Year
    • 6.2.5. Chart-Global Market by Application-Share by Year
    • 6.2.6. Chart-Global Market by Application-Segment Growth
  • 6.3. Global Market Organism - Overview
    • 6.3.1. Table-Global Market by Organism
    • 6.3.2. Chart-Global Market by Organism-Base/Final Year Comparison
    • 6.3.3. Chart-Global Market by Organism-Base Year
    • 6.3.4. Chart-Global Market by Organism-Final Year
    • 6.3.5. Chart-Global Market by Organism-Share by Year
    • 6.3.6. Chart-Global Market by Organism-Segment Growth

7. Global Whole Genome Sequencing Markets-By Application

  • 7.1. Research
    • 7.1.1. Table Research-by Country
    • 7.1.2. Chart - Research Growth
  • 7.2. Clinical Human
    • 7.2.1. Table Clinical Human-by Country
    • 7.2.2. Chart - Clinical Human Growth
  • 7.3. Clinical Tumor
    • 7.3.1. Table Clinical Tumor-by Country
    • 7.3.2. Chart - Clinical Tumor Growth
  • 7.4. Clinical Pathogen
    • 7.4.1. Table Clinical Pathogen-by Country
    • 7.4.2. Chart - Clinical Pathogen Growth
  • 7.5. Direct to Consumer
    • 7.5.1. Table Direct to Consumer-by Country
    • 7.5.2. Chart-Direct to Consumer Growth
  • 7.6. Agriculture/Other
    • 7.6.1. Table Agriculture/Other-by Country
    • 7.6.2. Chart-Agriculture/Other Growth

8. Global Whole Genome Sequencing Markets-by Organism

  • 8.1. Human
    • 8.1.1. Table Human-by Country
    • 8.1.2. Chart - Human Growth
  • 8.2. Pathogen
    • 8.2.1. Table Pathogen-by Country
    • 8.2.2. Chart - Pathogen Growth
  • 8.3. Other Organism
    • 8.3.1. Table Other Organism-by Country
    • 8.3.2. Chart - Other Organism Growth

9. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II The Whole Genome Sequence of SARS-CoV-2
  • III Methodology
  • II.1. Authors
  • II.2. Sources